Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy
JACC: Advances · 2025-02 · 4 (2) · 101511
DOI: 10.1016/j.jacadv.2024.101511 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2025-02. Verfasst von Ting-Wei Kao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) has recently gained recognition as a rare and fatal disease. Tafamidis, a first-in-class transthyretin stabilizer, has emerged as a promising agent for attenuating disease progression. Nevertheless, how tafamidis alters clinical and imaging parameters remains unclear. OBJECTIVES: This systemic review and meta-analysis aimed to investigate how tafamidis remodels the myocardium and influences the disease trajectory of ATTR-CM. METHODS: PubMed, EMBASE, and the Cochrane Library were searched for literature from inception to February 2024 which reported either the effects of tafamidis treatment or natural course of ATTR-CM. Outcomes of interests were all clinical and imaging parameters available from at least 2 independent studies. RESULTS: We identified 30 studies comprising 2,973 participants with ATTR-CM. Pooling all studies with outcomes of both tafamidis and placebo, tafamidis significantly reduced all-cause mortality (OR: 0.19; 95% CI: 0.07 to 0.56) and cardiovascular death (OR: 0.08; 95% CI: 0.02-0.30). Tafamidis also ameliorated the deterioration of 6-minute walk distance (standardized mean difference [SMD] 0.04 vs. -0.29, P = 0.002) and serum N-terminal pro-B-type natriuretic peptide level (SMD: -0.03 vs 0.41, P < 0.001). Regarding imaging parameters, better global longitudinal strain on echocardiography (SMD: 0.06 vs 0.50, P = 0.003), heart to contralateral ratio (SMD: -0.23 vs. -1.17, P = 0.037) on technetium-99m pyrophosphate scintigraphy, extracellular volume (P = 0.003), left (P < 0.001) and right (P = 0.001) ventricular ejection fraction, and right atrium area (P = 0.033) on cardiac magnetic resonance imaging were observed after tafamidis treatment. CONCLUSIONS: Tafamidis improves clinical outcomes and limits the progression of cardiac remodeling in ATTR-CM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Cardiovascular Centre, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan; Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan.
- Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan.
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Graduate Institute of Clinical Medicine, Taipei, Taiwan. Elec…
Förderung
- Pfizer
Zitieren
APA
Kao, T. W., Hung, Y. H., Yu, A. L., Cheng, M. F., Su, M. Y., Chao, C. C., Tsai, C. H., & Lin, Y. H. (2025). Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy. JACC: Advances, 4(2), 101511. https://doi.org/10.1016/j.jacadv.2024.101511
Vancouver
Kao TW, Hung YH, Yu AL, Cheng MF, Su MY, Chao CC, et al. Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy. JACC: Advances. 2025;4(2):101511. doi:10.1016/j.jacadv.2024.101511
BibTeX
@article{Kao2025,
author = {Kao, Ting-Wei and Hung, Yi-Hsin and Yu, An-Li and Cheng, Mei-Feng and Su, Mao-Yuan and Chao, Chi-Chao and Tsai, Cheng-Hsuan and Lin, Yen-Hung},
title = {Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy},
journal = {JACC: Advances},
year = {2025},
volume = {4},
number = {2},
pages = {101511},
doi = {10.1016/j.jacadv.2024.101511}
}
EUVIMED